阅读说明：本技术 Fgl2蛋白作为疟疾感染标志物的应用 (Application of FGL2 protein as malaria infection marker ) 是由 徐文岳 付雍 丁艳 谢佩芝 于 2019-10-17 设计创作，主要内容包括：本发明涉及FGL2蛋白作为疟疾感染标志物的应用,通过检测FGL2蛋白表达水平,判断和预示是否存在疟疾感染,提高疟疾检出率及降低误诊率并使疟疾患者第一时间得到有效救治；通过监控FGL2蛋白表达水平的变化,判断疟疾感染进程,为疟疾患者的疾病风险及治疗方案提供重要依据；通过检测FGL2蛋白表达水平,作为判断疟疾患者预后的重要指标。本发明无需特殊设备,操作简便,只需通过制备血清即可进行检测,患者在医院就医进行常规查血检验时即可。(The invention relates to application of FGL2 protein as a malaria infection marker, which judges and predicts whether malaria infection exists or not by detecting the expression level of FGL2 protein, improves the detection rate of malaria, reduces misdiagnosis rate and effectively treats malaria patients in the first time; by monitoring the change of the expression level of the FGL2 protein, the malaria infection process is judged, and an important basis is provided for the disease risk and the treatment scheme of malaria patients; the detection of FGL2 protein expression level is used as an important index for judging the prognosis of malaria patients. The invention does not need special equipment, is simple and convenient to operate, can carry out detection only by preparing serum, and can be used for routine blood examination and detection when patients seek medical advice in hospitals.)

Use of FGL2 protein as a marker for malaria infection.

2. The application according to claim 1, wherein the application comprises: judging and predicting whether malaria infection exists, judging the course of the malaria infection and judging the prognosis of malaria patients.

3. The use according to claim 2, wherein the presence or absence of malaria infection is judged and predicted by detecting the expression level of serum FGL2 protein, wherein the infected malarial parasites comprise: plasmodium falciparum, plasmodium vivax, plasmodium yoelii, plasmodium burgeri or plasmodium charelii.

4. The use of claim 2, wherein the progression of malaria infection is determined by monitoring changes in serum FGL2 protein expression levels, wherein the infected malarial parasites comprise: plasmodium yoelii, plasmodium berghei or plasmodium charantia.

5. The use of claim 2, wherein the prognosis of a patient with malaria is determined by measuring the expression level of serum FGL2 protein, wherein the infected malaria parasite comprises: plasmodium falciparum, plasmodium vivax, plasmodium yoelii, plasmodium burgeri or plasmodium charelii.

6. The use according to any one of claims 3 to 5, wherein the detection of the expression level of FGL2 protein is carried out by using an FGL2 protein detection kit.

7. The use according to any one of claims 3 to 5, wherein the serum is prepared by a method comprising: placing the blood sample in an incubator at 37 ℃ for 20min, then centrifuging at 10000rpm for 10min, and carefully collecting supernatant clear liquid, namely serum.

Technical Field

The invention belongs to the technical field of malaria detection, and relates to application of FGL2 protein as a malaria infection marker.

Background

Malaria is one of infectious diseases seriously harming public health, and at present, more than 40 million people still die in the world every year, and tuberculosis and AIDS are also called as three major infectious diseases in the world. The infection period of malaria in humans is divided into liver and erythrocytic stages, which are critical periods for the onset and death of malaria patients. However, since early symptoms of malaria in the erythrocytic stage are very similar to common diseases such as influenza and the like, misdiagnosis is often caused, so that malaria patients miss or delay the best treatment opportunity and cannot be cured in time, and if the malaria falciparum infection occurs, the disease progresses quite rapidly, and the malaria falciparum is reported to cause death of the patients within 14 days after the infection. Therefore, increasing the detection rate of malaria infection and reducing the rate of misdiagnosis will undoubtedly save the valuable lives of many malaria patients.

The current methods for malaria diagnosis are mainly pathogenic diagnosis (blood smear method) and immunological diagnosis (antigen-antibody method). The detection rate of blood smear is low, especially the plasmodium falciparum has the characteristic of adhering to the inner wall of host capillary, so that the protozoan rate in the peripheral blood of a malaria patient is extremely low and is difficult to detect. While immunological diagnostic methods are specific and have high detection rates, but it is necessary to establish that detection can be obtained when physicians are highly suspected of malaria infection, as described above, most malaria patients are often misdiagnosed due to similarity of disease symptoms, and preparation of plasmodium detection antibodies is cumbersome.

In addition, at present, no effective marker exists for judging, progressing and prognosing malarial patients. Therefore, the research of a simple and effective marker and a detection method has very important significance for improving the detection rate of malaria, indicating the disease process and judging prognosis.

Disclosure of Invention

In view of the above, the present invention aims to provide the use of FGL2 protein as a marker of malaria infection.

In order to achieve the purpose, the invention provides the following technical scheme:

the application of FGL2 protein as a malaria infection marker.

Preferably, the application comprises: judging and predicting whether malaria infection exists, judging the course of the malaria infection and judging the prognosis of malaria patients.

Further preferably, the presence or absence of malaria infection is judged and predicted by detecting the expression level of serum FGL2 protein, wherein the infected malarial parasite comprises: plasmodium falciparum, plasmodium vivax, plasmodium yoelii, plasmodium burgeri or plasmodium charelii.

Further preferably, the progression of malaria infection is determined by monitoring changes in the expression level of serum FGL2 protein, wherein the infected malaria parasites comprise: plasmodium yoelii, plasmodium berghei or plasmodium charantia.

Further preferably, the prognosis of a patient with malaria is determined by measuring the expression level of serum FGL2 protein, wherein the infected malaria parasite comprises: plasmodium falciparum, plasmodium vivax, plasmodium yoelii, plasmodium burgeri or plasmodium charelii.

Further preferably, the detection of the expression level of FGL2 protein is carried out by using an FGL2 protein detection kit.

More preferably, the serum is prepared by the following steps: placing the blood sample in an incubator at 37 ℃ for 20min, then centrifuging at 10000rpm for 10min, and carefully collecting supernatant clear liquid, namely serum.

The invention has the beneficial effects that:

the invention takes FGL2 protein as an effective marker of malaria infection, and the specific steps are as follows:

1. by detecting the expression level of the FGL2 protein, whether malaria infection exists or not is judged and predicted, the detection rate of malaria is improved, the misdiagnosis rate is reduced, and malaria patients are effectively cured at the first time;

2. by monitoring the change of the expression level of the FGL2 protein, the malaria infection process is judged, and an important basis is provided for the disease risk and the treatment scheme of malaria patients;

3. the detection of FGL2 protein expression level is used as an important index for judging the prognosis of malaria patients.

The invention does not need special equipment, is simple and convenient to operate, can carry out detection only by preparing serum, and can be used for routine blood examination and detection when patients seek medical advice in hospitals.

Drawings

In order to make the object, technical scheme and beneficial effect of the invention more clear, the invention provides the following drawings for explanation:

FIG. 1 shows the expression level of FGL2 in the serum of human malaria patients.

FIGS. 2 a-2 c show the rate of plasmodium yoelii infecting mouse protozoa and the expression level of FGL2 in serum.

FIGS. 3 a-3 c show the rate of plasmodium xiae infecting mouse protozoa and the expression level of FGL2 in serum.

FIGS. 4 a-4 c show the rate of P.burgei infection in mice and the level of FGL2 expression in serum.

FIGS. 5 a-5 b are the correlation analysis of the protozoan rate of Plasmodium urealy infecting mice and the expression level of FGL 2.

FIGS. 6 a-6 b are the correlation analysis of the protozoan rate of Plasmodium yoelii infected mice and the expression level of FGL 2.

FIGS. 7 a-7 b are the correlation analysis of the protozoan rate of P.burgei infected mice and the expression level of FGL 2.

Detailed Description

Preferred embodiments of the present invention will be described in detail below with reference to the accompanying drawings.